These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 6508821)

  • 81. Modulation of human ovarian tumor cell sensitivity to N-(phosphonacetyl)-L-aspartate (PALA) by liposome drug carriers.
    Sharma A; Straubinger NL; Straubinger RM
    Pharm Res; 1993 Oct; 10(10):1434-41. PubMed ID: 8272404
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Bohr effect in Escherichia coli aspartate transcarbamylase. Linkages between substrate binding, proton binding, and conformational transitions.
    Allwell NM; Hofmann GE; Zaug A; Lennick M
    Biochemistry; 1979 Jul; 18(14):3008-15. PubMed ID: 37893
    [No Abstract]   [Full Text] [Related]  

  • 83. Calorimetric analysis of aspartate transcarbamylase from Escherichia coli. Binding of substrates and substrate analogues to the native enzyme and catalytic subunit.
    Knier BL; Allewell NM
    Biochemistry; 1978 Mar; 17(5):784-90. PubMed ID: 343809
    [No Abstract]   [Full Text] [Related]  

  • 84. m-AMSA and PALA: two new agents in cancer chemotherapy.
    Rozencweig M; Von Hoff DD; Cysyk RL; Muggia FM
    Cancer Chemother Pharmacol; 1979; 3(3):135-41. PubMed ID: 393427
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Escherichia coli aspartate transcarbamylase: a novel marker for studies of gene amplification and expression in mammalian cells.
    Ruiz JC; Wahl GM
    Mol Cell Biol; 1986 Sep; 6(9):3050-8. PubMed ID: 3537729
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Drug resistance and gene amplification potential regulated by transforming growth factor beta 1 gene expression.
    Huang A; Jin H; Wright JA
    Cancer Res; 1995 Apr; 55(8):1758-62. PubMed ID: 7712485
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Neurotoxicity of the pyrimidine synthesis inhibitor N-phosphonoacetyl-L-aspartate.
    Wiley RG; Gralla RJ; Casper ES; Kemeny N
    Ann Neurol; 1982 Aug; 12(2):175-83. PubMed ID: 7125606
    [TBL] [Abstract][Full Text] [Related]  

  • 88. A kinetic model of cooperativity in aspartate transcarbamylase.
    Dembo M; Rubinow SI
    Biophys J; 1977 Jun; 18(3):245-67. PubMed ID: 329911
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Picosecond dynamics of T and R forms of aspartate transcarbamylase: a neutron scattering study.
    Zanotti JM; Hervé G; Bellissent-Funel MC
    Biochim Biophys Acta; 2006 Oct; 1764(10):1527-35. PubMed ID: 17008138
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Synthesis and in vitro evaluation of aspartate transcarbamoylase inhibitors.
    Coudray L; Pennebaker AF; Montchamp JL
    Bioorg Med Chem; 2009 Nov; 17(22):7680-9. PubMed ID: 19828320
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Antipyrimidine effects of five different pyrimidine de novo synthesis inhibitors in three head and neck cancer cell lines.
    Peters GJ
    Nucleosides Nucleotides Nucleic Acids; 2018; 37(6):329-339. PubMed ID: 29723133
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Gross quaternary changes in aspartate carbamoyltransferase are induced by the binding of N-(phosphonacetyl)-L-aspartate: A 3.5-A resolution study.
    Ladner JE; Kitchell JP; Honzatko RB; Ke HM; Volz KW; Kalb AJ; Ladner RC; Lipscomb WN
    Proc Natl Acad Sci U S A; 1982 May; 79(10):3125-8. PubMed ID: 6954462
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Gene amplification and microsatellite instability induced in tumorigenic human bronchial epithelial cells by alpha particles and heavy ions.
    Piao CQ; Hei TK
    Radiat Res; 2001 Jan; 155(1 Pt 2):263-267. PubMed ID: 11121244
    [TBL] [Abstract][Full Text] [Related]  

  • 94. The catalytic site of Escherichia coli aspartate transcarbamylase: interaction between histidine 134 and the carbonyl group of the substrate carbamyl phosphate.
    Xi XG; Van Vliet F; Ladjimi MM; Cunin R; Hervé G
    Biochemistry; 1990 Sep; 29(36):8491-8. PubMed ID: 2252907
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Aspartate transcarbamylase from Leishmania donovani. A discrete, nonregulatory enzyme as a potential chemotherapeutic site.
    Mukherjee T; Ray M; Bhaduri A
    J Biol Chem; 1988 Jan; 263(2):708-13. PubMed ID: 2891701
    [TBL] [Abstract][Full Text] [Related]  

  • 96. N-(phosphonacetyl)-L-aspartate, a potent transition state analog inhibitor of aspartate transcarbamylase, blocks proliferation of mammalian cells in culture.
    Swyryd EA; Seaver SS; Stark GR
    J Biol Chem; 1974 Nov; 249(21):6945-50. PubMed ID: 4371054
    [No Abstract]   [Full Text] [Related]  

  • 97. Submicromolar phosphinic inhibitors of Escherichia coli aspartate transcarbamoylase.
    Coudray L; Kantrowitz ER; Montchamp JL
    Bioorg Med Chem Lett; 2009 Feb; 19(3):900-2. PubMed ID: 19097895
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Unexpected synergy between N-phosphonacetyl-L-aspartate and cytidine against human tumor cells.
    Chan TC; Howell SB
    Eur J Cancer Clin Oncol; 1989 Apr; 25(4):721-7. PubMed ID: 2714348
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Gene amplification causes overproduction of the first three enzymes of UMP synthesis in N-(phosphonacetyl)-L-aspartate-resistant hamster cells.
    Wahl GM; Padgett RA; Stark GR
    J Biol Chem; 1979 Sep; 254(17):8679-89. PubMed ID: 381311
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Aspartate transcarbamylase of Escherichia coli. Mechanisms of inhibition and activation by dicarboxylic acids and other anions.
    Jacobson GR; Stark GR
    J Biol Chem; 1975 Sep; 250(17):6852-60. PubMed ID: 1099096
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.